Dr Thomas Pulliam
Grant-Funded Researcher (B)
SAIGENCI
College of Health
Dr Thomas Pulliam is a postdoctoral research fellow in the lab of Professor Lisa Butler where he undertakes prostate cancer research including treatment response prediction, testing the efficacy of novel drugs, spatial multiomics, nutrition/diet studies, and lipid metabolism.
Dr Pulliam recieved his PhD in Cell and Molecular Biology from the Univeristy of Houston in 2021. He conducted his postdoctoral training at MD Anderson Cancer Center in Houston, Texas where he studied the interaction of androgen receptor (AR) signaling, metabolism, and angiogensis in advanced stage prostate cancer. He also aided in the development of novel inhibitors of Calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2), an AR regulated gene shown to drive prostate cancer progression through metabolic adaptation.
| Date | Position | Institution name |
|---|---|---|
| 2026 - ongoing | Postdoctoral Fellow | University of Adelaide |
| 2021 - 2026 | Postdoctoral Fellow | The University of Texas MD Anderson Cancer Center |
| 2017 - 2021 | Graduate Research Assistant | University of Houston |
| 2015 - 2017 | Graduate Teaching Assistant | University of Houston |
| 2014 - 2014 | Beach Water Sample Analyzer | Texas General Land Office |
| 2008 - 2012 | Chemical, Biological, Radiological, Nuclear Defense Specialist | United States Marine Corps |
| Date | Institution name | Country | Title |
|---|---|---|---|
| 2015 - 2021 | University of Houston | United States | PhD |
| 2012 - 2014 | Lamar University | United States | Bachelors |
| Date | Title | Institution | Country |
|---|---|---|---|
| 2026 | Postdoctoral Fellow | University of Adelaide | Australia |
| 2021 - 2026 | Postdoctoral Fellow | The University of Texas MD Anderson Cancer Center | United States |
| Year | Citation |
|---|---|
| 2025 | Lin, C., Pulliam, T. L., Han, J. J., Xu, J., Recio, C. V., Wilkenfeld, S. R., . . . Frigo, D. E. (2025). Cholesterol metabolism regulated by CAMKK2-CREB signaling promotes castration-resistant prostate cancer. Cell Reports, 44(6), 115792. |
| 2024 | Awad, D., Cao, P. H. A., Pulliam, T. L., Spradlin, M., Subramani, E., Tellman, T. V., . . . Frigo, D. E. (2024). Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity.. Cancer research, 84(5), 703-724. WoS22 Europe PMC20 |
| 2022 | Pulliam, T. L., Goli, P., Awad, D., Lin, C., Wilkenfeld, S. R., & Frigo, D. E. (2022). Regulation and role of CAMKK2 in prostate cancer. NATURE REVIEWS UROLOGY, 19(6), 367-380. WoS29 Europe PMC30 |
| 2022 | Pulliam, T. L., Awad, D., Han, J. J., Murray, M. M., Ackroyd, J. J., Goli, P., . . . Frigo, D. E. (2022). Systemic Ablation of <i>Camkk2</i> Impairs Metastatic Colonization and Improves Insulin Sensitivity in TRAMP Mice: Evidence for Cancer Cell-Extrinsic CAMKK2 Functions in Prostate Cancer. CELLS, 11(12), 19 pages. WoS9 Europe PMC11 |
| 2021 | Lin, C., Blessing, A. M., Pulliam, T. L., Shi, Y., Wilkenfeld, S. R., Han, J. J., . . . Frigo, D. E. (2021). Inhibition of CAMKK2 impairs autophagy and castration-resistant prostate cancer via suppression of AMPK-ULK1 signaling. ONCOGENE, 40(9), 1690-1705. WoS47 Europe PMC51 |
| 2021 | Eduful, B. J., O'Byrne, S. N., Temme, L., Asquith, C. R. M., Liang, Y., Picado, A., . . . Drewry, D. H. (2021). Hinge Binder Scaffold Hopping Identifies Potent Calcium/Calmodulin-Dependent Protein Kinase Kinase 2 (CAMKK2) Inhibitor Chemotypes. JOURNAL OF MEDICINAL CHEMISTRY, 64(15), 10849-10877. WoS24 Europe PMC23 |
| 2018 | Awad, D., Pulliam, T. L., Lin, C., Wilkenfeld, S. R., & Frigo, D. E. (2018). Delineation of the androgen-regulated signaling pathways in prostate cancer facilitates the development of novel therapeutic approaches. CURRENT OPINION IN PHARMACOLOGY, 41, 1-11. WoS10 Europe PMC9 |
| 2018 | White, M. A., Tsouko, E., Lin, C., Rajapakshe, K., Spencer, J. M., Wilkenfeld, S. R., . . . Frigo, D. E. (2018). GLUT12 promotes prostate cancer cell growth and is regulated by androgens and CaMKK2 signaling. ENDOCRINE-RELATED CANCER, 25(4), 453-469. WoS53 Europe PMC51 |
| Year | Citation |
|---|---|
| 2019 | Lin, C., Salzillo, T. C., Bader, D. A., Wilkenfeld, S. R., Awad, D., Pulliam, T. L., . . . Frigo, D. E. (2019). Prostate Cancer Energetics and Biosynthesis. In S. M. Dehm, & D. J. Tindall (Eds.), PROSTATE CANCER: CELLULAR AND GENETIC MECHANISMS OF DISEASE DEVELOPMENT AND PROGRESSION, 2ND EDITION (Vol. 1210, pp. 185-237). SPRINGER INTERNATIONAL PUBLISHING AG. DOI WoS28 Europe PMC27 |
| Year | Citation |
|---|---|
| 2022 | Awad, D., Pulliam, T., Spradlin, M., Cao, P. H. -A., Subramani, E., Tellman, T., . . . Frigo, D. (2022). Adipose triglyceride lipase is regulated by CAMKK2-AMPK signaling and drives advanced prostate cancer. DOI |
| 2022 | Wells, C., Liang, Y., Pulliam, T., Lin, C., Awad, D., Eduful, B., . . . Drewry, D. (2022). SGC-CAMKK2-1: A chemical probe for CAMKK2. DOI |
| 2020 | Lin, C., Blessing, A., Pulliam, T., Shi, Y., Wilkenfeld, S., Han, J., . . . Frigo, D. (2020). Inhibition of CAMKK2 impairs autophagy and castration-resistant prostate cancer via suppression of AMPK-ULK1 signaling. DOI |
Connect With Me
External Profiles
